Targeting tumor metabolism in IDH‑mutant grade 4 astrocytoma
Targeting metabolic vulnerabilities in Astrocytoma, IDH-mutant, Grade 4
People with IDH‑mutant grade 4 astrocytoma will get a short presurgery dose of a brain‑penetrant drug that blocks nucleotide metabolism to look for early effects on the tumor.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11164786 on NIH RePORTER |
What this research studies
You would be eligible if your tumor has an IDH1 or IDH2 mutation and you are scheduled for surgery. Before surgery you'll receive a short course of a brain‑penetrant drug that interferes with nucleotide metabolism, and tumor tissue removed at surgery will be analyzed for signs the drug worked. Laboratory and molecular tests will look for tumor cell death and metabolic changes caused by the drug compared with untreated samples. This is an early surgical window (phase 0) trial designed to guide future, larger clinical studies.
Who could benefit from this research
Good fit: Adults diagnosed with IDH‑mutant grade 4 astrocytoma who are scheduled for surgical tumor resection and meet medical safety criteria.
Not a fit: Patients whose tumors do not have an IDH1/2 mutation, those not undergoing surgery, or people who cannot safely receive the study drug are unlikely to benefit from this trial.
Why it matters
Potential benefit: If successful, this approach could point to a tumor‑selective therapy for IDH‑mutant gliomas and accelerate development of new treatments.
How similar studies have performed: Preclinical studies show nucleotide‑metabolism inhibitors preferentially kill IDH‑mutant glioma cells, but this surgical window trial is an early clinical test and broader clinical benefit remains unproven.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Batchelor, Tracy T — Brigham and Women's Hospital
- Study coordinator: Batchelor, Tracy T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.